AMD/RETINA

In patients with neovascular age-related macular disease (nAMD), a treat-and-extend (T&E) dosing regimen with ranibizumab resulted in clinically meaningful improvement in best-corrected visual acuity (BCVA) that was not worse compared with monthly treatment through 24 months, according to results of a study published in JAMA Ophthalmology.

In this randomized, open-label, multicenter, noninferiority intention-to-treat…

View Conference Coverage

Take a look at some of our conference coverage, visit our roundup section.

Conference Roundup

  1. Oct 15, 2019

AAO 2019: Positive Efficacy Data Presented for Trial of hRPC Stem Cell Therapy

ReNeuron announced at the AAO 2019 meeting positive clinical data for its Phase 1/2a clinical trial of hRPC stem cell therapy for retinitis pigmentosa.

The ongoing trial is an open-label study to evaluate the safety, tolerability, and efficacy of…

Journal Scan

  1. Jan 14, 2020

Treat-and-extend Regimen with Ranibizumab Comparable with Monthly Treatment in Patients with nAMD

In patients with neovascular age-related macular disease (nAMD), a treat-and-extend (T&E) dosing regimen with ranibizumab resulted in clinically meaningful improvement in best-corrected visual acuity (BCVA) that was…